Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61) | References | |
Homo sapiens | integrin, alpha 2b (platelet glycoprotein IIb of IIb/IIIa complex, antigen CD41) | Starlite/ChEMBL | References |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | fructose-16-bisphosphatase-related | 0.0724 | 0.7701 | 1 |
Schistosoma mansoni | integrin beta subunit | 0.0223 | 0.2031 | 0.2637 |
Leishmania major | 0.0724 | 0.7701 | 0.5 | |
Echinococcus granulosus | fructose 16 bisphosphatase 1 | 0.0724 | 0.7701 | 1 |
Toxoplasma gondii | fructose-bisphospatase II | 0.0724 | 0.7701 | 1 |
Trypanosoma cruzi | fructose-1,6-bisphosphatase, cytosolic, putative | 0.0724 | 0.7701 | 1 |
Trypanosoma cruzi | fructose-1,6-bisphosphatase, cytosolic, putative | 0.0724 | 0.7701 | 1 |
Echinococcus multilocularis | fructose 1,6 bisphosphatase 1 | 0.0724 | 0.7701 | 0.7593 |
Echinococcus multilocularis | survival motor neuron protein 1 | 0.0271 | 0.2571 | 0.2222 |
Brugia malayi | hypothetical protein | 0.0057 | 0.0162 | 0.0034 |
Echinococcus multilocularis | integrin beta 2 | 0.028 | 0.268 | 0.2337 |
Brugia malayi | Integrin alpha cytoplasmic region family protein | 0.014 | 0.1092 | 0.1263 |
Brugia malayi | Integrin beta pat-3 precursor | 0.0378 | 0.3789 | 0.4828 |
Loa Loa (eye worm) | fructose-1,6-bisphosphatase | 0.0724 | 0.7701 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0102 | 0.0664 | 0.0863 |
Brugia malayi | fructose-1,6-bisphosphatase | 0.0724 | 0.7701 | 1 |
Brugia malayi | Kelch motif family protein | 0.0057 | 0.0162 | 0.0034 |
Loa Loa (eye worm) | integrin beta-2 | 0.0378 | 0.3789 | 0.492 |
Schistosoma mansoni | hypothetical protein | 0.0055 | 0.0136 | 0.0177 |
Echinococcus granulosus | survival motor neuron protein 1 | 0.0271 | 0.2571 | 0.2926 |
Brugia malayi | Integrin alpha pat-2 precursor | 0.0185 | 0.16 | 0.1935 |
Loa Loa (eye worm) | hypothetical protein | 0.0271 | 0.2571 | 0.3339 |
Schistosoma mansoni | integrin alpha-ps | 0.0083 | 0.0449 | 0.0583 |
Brugia malayi | hypothetical protein | 0.0271 | 0.2571 | 0.3218 |
Echinococcus multilocularis | integrin alpha 3 | 0.0142 | 0.1113 | 0.0696 |
Trypanosoma brucei | fructose-1,6-bisphosphatase | 0.0724 | 0.7701 | 1 |
Echinococcus granulosus | integrin beta 2 | 0.028 | 0.268 | 0.3077 |
Loa Loa (eye worm) | hypothetical protein | 0.014 | 0.1092 | 0.1418 |
Onchocerca volvulus | 0.0055 | 0.0136 | 0.5 | |
Schistosoma mansoni | integrin alpha | 0.0185 | 0.16 | 0.2078 |
Echinococcus granulosus | integrin alpha 3 | 0.0142 | 0.1113 | 0.0916 |
Schistosoma mansoni | survival motor neuron protein | 0.0055 | 0.0136 | 0.0177 |
Loa Loa (eye worm) | integrin alpha pat-2 | 0.0285 | 0.2731 | 0.3546 |
Loa Loa (eye worm) | hypothetical protein | 0.0057 | 0.0162 | 0.0211 |
Loa Loa (eye worm) | kelch domain-containing protein family protein | 0.0057 | 0.0162 | 0.0211 |
Loa Loa (eye worm) | hypothetical protein | 0.0145 | 0.1152 | 0.1496 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 0.11 uM | Concentration required to reduce binding of fibrinogen to purified Fibrinogen Receptor by 50% using ELISA | ChEMBL. | 9207949 |
IC50 (binding) | = 0.11 uM | Concentration required to reduce binding of fibrinogen to purified Fibrinogen Receptor by 50% using ELISA | ChEMBL. | 9207949 |
IC50 (functional) | = 1.2 uM | Ability to block Glyocoprotein IIb-IIIa was measured by inhibiting ADP induced human platelet aggregation (5 uM) | ChEMBL. | 9207949 |
IC50 (functional) | = 1.2 uM | Ability to block Glyocoprotein IIb-IIIa was measured by inhibiting ADP induced human platelet aggregation (5 uM) | ChEMBL. | 9207949 |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Homo sapiens | ChEMBL23 | 9207949 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.